Balaxi Pharmaceuticals' Q3 FY 2025-26 Quarterly Results
- 29 Jan 2026
Result Summary
- Balaxi Pharmaceuticals Ltd reported a 25.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 5.9%.
- Its expenses for the quarter were up by 26.0% QoQ and down 0.2% YoY.
- The net profit increased 42.9% QoQ and decreased 94.4% YoY.
- The earnings per share (EPS) of Balaxi Pharmaceuticals Ltd stood at 0.06 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 72.64 | 57.76 | 77.23 | 25.8% | -5.9% |
Total Expenses | 71.03 | 56.38 | 71.16 | 26.0% | -0.2% |
Profit Before Tax | 1.61 | 1.38 | 6.07 | 16.7% | -73.5% |
Tax | 1.30 | 1.17 | 0.71 | 11.1% | 83.1% |
Profit After Tax | 0.30 | 0.21 | 5.36 | 42.9% | -94.4% |
Earnings Per Share | 0.06 | 0.04 | 0.97 | 50.0% | -93.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Balaxi Pharmaceuticals Ltd is a company engaged in the pharmaceutical industry, primarily focusing on the distribution and marketing of generic pharmaceutical products. The company operates in international markets, leveraging its distribution network to provide access to essential medicines. As of the latest available data, Balaxi Pharmaceuticals has not disclosed any recent major developments or significant shifts in its business operations. The company's primary business strategy revolves around expanding its product portfolio and geographical reach to enhance its market presence.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Balaxi Pharmaceuticals Ltd reported a total income of ₹72.64 crores. This represents a quarter-over-quarter (QoQ) increase of 25.8% from ₹57.76 crores in Q2FY26. However, on a year-over-year (YoY) basis, there was a decline of 5.9% compared to ₹77.23 crores in Q3FY25. This data indicates a significant rebound in revenue from the previous quarter but a decrease compared to the same period last year. The factors contributing to these changes are not detailed in the available data.
Profitability
For the period of Q3FY26, Balaxi Pharmaceuticals Ltd recorded a profit before tax of ₹1.61 crores, marking a 16.7% QoQ increase from ₹1.38 crores in Q2FY26. However, this figure reflects a substantial YoY decrease of 73.5% from ₹6.07 crores in Q3FY25. The company incurred taxes amounting to ₹1.30 crores, which increased by 11.1% QoQ from ₹1.17 crores, and grew by 83.1% YoY from ₹0.71 crores. Consequently, the profit after tax for Q3FY26 stood at ₹0.30 crores, up by 42.9% QoQ from ₹0.21 crores but down by 94.4% YoY from ₹5.36 crores. Earnings per share (EPS) for the quarter was ₹0.06, reflecting a 50.0% QoQ increase from ₹0.04 but a 93.8% YoY decline from ₹0.97.
Operating Metrics
The operating expenses for Balaxi Pharmaceuticals Ltd in Q3FY26 were ₹71.03 crores, which shows a QoQ increase of 26.0% from ₹56.38 crores in Q2FY26 and a slight YoY decrease of 0.2% from ₹71.16 crores in Q3FY25. This indicates that while expenses have grown from the last quarter, they have remained relatively stable compared to the previous year. The company's ability to manage its expenses in relation to its income is critical for its financial health, though specifics on cost management strategies are not provided in the data.